Modern H1 antihistamines in the treatment of patients with allergic rhinitis and comorbid acute respiratory infections

Овчинников, А. Ю.; Мирошниченко, Н А; Nikolaeva, Yu.O.

doi:10.17116/otorino20228703130

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among all the candidate drugs, we selected three drug molecules in the study. Cetirizine, as an anti‐allergic drug, had shown its effect on GERD and respiratory diseases in previous studies [ 53 , 54 ]. Luteolin played an anti‐pulmonary fibrosis role in IPF via the regulation of inflammation and pro‐fibrotic signalling pathways [ 55 ], while luteolin had an impact on the prognosis of GERD mainly through inflammatory modulating effects [ 56 ].…”

Section: Discussionmentioning

confidence: 99%

Prediction and analysis of genetic effect in idiopathic pulmonary fibrosis and gastroesophageal reflux disease

Chen,

Xie,

et al. 2023

IET Systems Biology

View full text Add to dashboard Cite

With increasing research on idiopathic pulmonary fibrosis (IPF) and gastroesophageal reflux disease (GERD), more and more studies have indicated that GERD is associated with IPF, but the underlying pathological mechanisms remain unclear. The aim of the present study is to identify and analyse the differentially expressed genes (DEGs) between IPF and GERD and explore the relevant molecular mechanisms via bioinformatics analysis. Four GEO datasets (GSE24206, GSE53845, GSE26886, and GSE39491) were downloaded from the GEO database, and DEGs between IPF and GERD were identified with the online tool GEO2R. Subsequently, a series of bioinformatics analyses are conducted, including Kyoto Encyclopaedia of Genes and Genomes (KEGG) and gene ontology (GO) enrichment analyses, the PPI network, biological characteristics, TF‐gene interactions, TF‐miRNA coregulatory networks, and the prediction of drug molecules. Totally, 71 genes were identified as DEGs in IPF and GERD. Five KEGG pathways, including Amoebiasis, Protein digestion and absorption, Relaxin signalling pathway, AGE‐RAGE signalling pathway in diabetic complications, and Drug metabolism ‐ cytochrome P450, were significantly enriched. In addition, eight hub genes, including POSTN, MMP1, COL3A1, COL1A2, CXCL12, TIMP3, VCAM1, and COL1A1 were selected from the PPI network by Cytoscape software. Then, five hub genes (MMP1, POSTN, COL3A1, COL1A2, and COL1A1) with high diagnostic values for IPF and GERD were validated by GEO datasets. Finally, TF‐gene and miRNA interaction was identified with hub genes and predicted drug molecules for the IPF and GERD. And the results suggest that cetirizine, luteolin, and pempidine may have great potential therapeutic value in IPF and GERD. This study will provide novel strategies for the identification of potential biomarkers and valuable therapeutic targets for IPF and GERD.

show abstract

Section: Discussionmentioning

confidence: 99%

Prediction and analysis of genetic effect in idiopathic pulmonary fibrosis and gastroesophageal reflux disease

Chen,

Xie,

et al. 2023

IET Systems Biology

View full text Add to dashboard Cite

show abstract

Therapy of acute rhinosinusitis in patients with allergic rhinitis: possibilities for implementing advanced control of inflammation

Svistushkin,

Nikiforova,

Kiselev

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. Allergic rhinitis (AR) in conjunction with acute infectious rhinosinusitis (ARS) can lead to increased inflammation and contributes to a more severe course of ARS.Aim. To study the effect of some non-sedating H1-antihistamines on the severity of clinical presentations in adult patients with ARS and underlying AR as part of routine medical practice.Materials and methods. Group 1 (75 patients) and Group 2 (85 patients) were generated through simple randomization from the patient population with ARS and underlying AR, who were prescribed benzhydryl-piperazinyl-butylmethylxanthine succinate (Teoritin® MF, 4 mg/day) or desloratadine (INN, 5 mg/day), respectively. The course of therapy was 14 days. The estimated parameters included changes in indices of nasal symptoms, rhinoscopic and non-nasal symptoms during follow-up visits, time to reach zero indices, the proportions of patients, whose symptoms reduced after 3 and 7 days of treatment, the need for the use of nasal decongestants and changes in quality of life measures.Results and discussion. During the first 3 days of treatment, nasal breathing improved in 91% (95% CI 81–96%) of patients in Group 1 vs 56% (95% CI 45–67%) in Group 2, p < 0.001; rhinorrhea was relieved in 76% (95% CI 65–85%) and 62% (95% CI 51–72%) in Groups 1 and 2, respectively. By Day 7 of treatment, complete restoration of nasal breathing was observed in 71% of patients in Group 1 (95% CI 59–80%), and in 41% (95% CI 31–52%) in Group 2 (p = 0.014); rhinorrhea was relieved in 61%(95% CI 49–72%) of patients in Group 1 and 37% (95% CI 27–48%) in Group 2, p = 0.001. Decongestants were used by 20%(95% CI 12–31%) of patients in Group 1, and by 35% (95% CI 25–47%) of patients in Group 2, p = 0.031. The between-group difference was significant in terms of duration and frequency of adjuvant therapy, p < 0.05.Conclusion. In comparison with desloratadine, it provided a more pronounced reduction of nasal and non-nasal symptoms, as well as relief of rhinoscopic signs of inflammation in a shorter time. The use of Teoritin® MF contributed to the reduction in the need (duration and frequency) for nasal decongestants.

show abstract

Modern H1 antihistamines in the treatment of patients with allergic rhinitis and comorbid acute respiratory infections

Cited by 2 publications

References 19 publications

Prediction and analysis of genetic effect in idiopathic pulmonary fibrosis and gastroesophageal reflux disease

Prediction and analysis of genetic effect in idiopathic pulmonary fibrosis and gastroesophageal reflux disease

Therapy of acute rhinosinusitis in patients with allergic rhinitis: possibilities for implementing advanced control of inflammation

Contact Info

Product

Resources

About